Accurate De Novo Antibody Sequencing for Human & Humanized mAbs

Q: What is de novo antibody sequencing, and why is it important?

De novo antibody sequencing is the process of determining the complete amino acid sequence of an antibody directly from the purified protein itself, without any prior knowledge of the DNA, RNA, or the hybridoma cell line that produced it. This technology is critical for several reasons: Rescuing Valuable Antibodies: When a hybridoma cell line is lost, becomes unstable, or undergoes genetic drift, de novo sequencing is the only way to perfectly preserve the antibody's sequence for future recombinant production. Securing Intellectual Property: A precise and verified amino acid sequence is an indispensable component of a strong patent application for a novel antibody therapeutic. Accelerating Biosimilar Development: The foundational first step in creating a biosimilar drug is to obtain the exact sequence of the originator molecule. Ensuring Reproducibility: Inconsistent results between different antibody batches can derail research. Sequencing confirms the identity of the antibody, eliminating sequence variation as a source of discrepancy.

Q: Is your service applicable to antibodies from non-human species?

Absolutely. Our de novo sequencing platform is species-agnostic and has been successfully used to sequence antibodies from a wide variety of species, including mouse, rat, rabbit, camelid, chicken, and more. While this page focuses on human/humanized antibodies, our technology and expertise are fully capable of sequencing an antibody from any species. Please visit our related service pages or contact us directly.

Background Workflow Highlight Advantage Related Services FAQ Online Inquiry

In the intricate world of therapeutic antibody development, diagnostics, and academic research, the primary amino acid sequence of a monoclonal antibody is the foundational blueprint. Without this precise code, advancing a candidate, ensuring batch-to-batch reproducibility, or securing intellectual property is an exercise in uncertainty. Creative Biolabs, a vanguard in antibody solutions with over two decades of expertise, offers a premier De Novo Human/Humanized Antibody Sequencing Service, leveraging state-of-the-art mass spectrometry and proprietary bioinformatics to deliver the definitive sequence with unparalleled accuracy and completeness. This service is engineered to empower researchers and developers by providing the exact amino acid sequence of any human or humanized antibody, directly from the purified protein, without any prior knowledge of the DNA or hybridoma cell line.

Discuss Your Project Today

The Critical Imperative: Why De Novo Antibody Sequencing is Non-Negotiable

The journey of a therapeutic antibody from discovery to clinic is paved with challenges. Hybridoma cell lines can be lost or genetically drift, legacy antibodies may lack complete documentation, and the complexities of the immune repertoire demand precise characterization. In these scenarios, de novo sequencing becomes the indispensable tool for progress.

Key challenges that necessitate precise sequencing include:

Hybridoma Instability and Loss: The risk of losing a valuable antibody-producing hybridoma cell line is a constant threat. De Novo Sequencing provides the ultimate insurance policy, capturing the antibody's genetic code for perpetual recombinant production.
Intellectual Property and Patent Filing: A precise, verified amino acid sequence is a cornerstone of any robust patent application for a novel antibody therapeutic.
Biosimilar and Biobetter Development: Accurately sequencing an originator molecule is the first and most critical step in developing a biosimilar. Furthermore, understanding the precise sequence enables targeted engineering for "biobetter" candidates with improved characteristics.
Humanization and Affinity Maturation: To reduce immunogenicity and enhance efficacy, murine or other non-human antibodies are "humanized." This process requires exact knowledge of the original complementarity-determining regions (CDRs) to graft onto a human framework. De novo sequencing provides this essential CDR information with 100% certainty.
Ensuring Reproducibility: Inconsistencies between antibody batches can derail research and diagnostic assays. Sequencing confirms the identity of the antibody, ensuring that observed functional differences are not due to sequence variations.

Fig. 1 Antibody sequencing. (OA Literature) Fig. 1 Graphic representation of antibody sequencing.¹

Our De Novo Human/Humanized Antibody Sequencing Workflow

We have refined our service into a seamless, transparent, and efficient process, designed to take you from sample submission to full sequence data with speed and confidence.

Step	Description
1. Project Initiation	Consultation with our Ph.D.-level experts to define project scope and objectives. Submission of 50-100 µg of purified antibody (>95% purity).
2. Sample QC & Digestion	Rigorous quality control of the submitted antibody via SDS-PAGE and intact mass analysis. Strategic digestion with a panel of 5-8 orthogonal enzymes to generate overlapping peptides.
3. LC-MS/MS Data Acquisition	High-resolution tandem mass spectrometry is performed on the peptide fragments. Multiple fragmentation methods (CID, HCD, ETD) are employed to maximize sequence information.
4. Sequence Assembly	Our proprietary de novo sequencing algorithms assemble the peptide reads into full-length heavy and light chain sequences. This includes definitive I/L determination and PTM identification.
5. Data Analysis & Verification	The assembled sequence is cross-verified against the intact mass of the antibody chains. Framework (FR) and CDR regions are annotated. A final, comprehensive report is generated.
6. Reporting & Delivery	Secure delivery of the final report, which includes full amino acid sequences, V(D)J gene annotation, peptide coverage maps, and all supporting mass spectrometry data.

The Creative Biolabs Highlights: Precision Forged by Technology

At the heart of our De Novo Human/Humanized Antibody Sequencing Service is our proprietary technology platform. We have moved beyond the limitations of traditional sequencing methods, integrating cutting-edge mass spectrometry with sophisticated bioinformatic algorithms to resolve the most complex antibody structures.

Our technological cornerstone is the Database Assisted Shotgun Sequencing (DASS) platform, a multi-faceted approach that guarantees 100% coverage and accuracy.

Key Technological Highlights

Multi-Enzymatic Digestion Strategy: We utilize a panel of at least five complementary proteases (e.g., Trypsin, Chymotrypsin, Glu-C) to digest the antibody. This orthogonal approach generates a rich library of overlapping peptide fragments, ensuring that every single amino acid, from the N-terminus to the C-terminus of both heavy and light chains, is covered multiple times.
High-Resolution Mass Spectrometry: Our laboratories are equipped with the latest generation of mass spectrometers, such as the Orbitrap Fusion Lumos. These instruments provide exceptional mass accuracy and sensitivity, allowing for the confident identification of peptides and their post-translational modifications (PTMs).
The Isoleucine/Leucine Conundrum Solved: A significant hurdle in mass spectrometry-based sequencing is the inability to distinguish between the isobaric amino acids Leucine (L) and Isoleucine (I). Creative Biolabs has pioneered proprietary fragmentation and data analysis techniques that definitively resolve this ambiguity, a critical capability for ensuring the functional integrity of a recombinantly produced antibody.
Advanced Bioinformatic Pipeline: The immense volume of spectral data is processed by our sophisticated software suite. Our algorithms expertly assemble the overlapping peptide fragments, reconstruct the full-length sequences of the variable and constant regions, and accurately delineate the crucial CDRs.

Why Partner with Creative Biolabs?

Choosing a partner for a service as critical as antibody sequencing is a decision that impacts the trajectory of your entire project. With Creative Biolabs, you gain more than a service provider; you gain a dedicated scientific partner.

Unwavering Accuracy: We guarantee 100% sequence accuracy, including the definitive differentiation of Isoleucine and Leucine.
Decades of Expertise: Our team consists of seasoned experts in proteomics, mass spectrometry, and antibody engineering who have successfully sequenced thousands of antibodies.
Technological Supremacy: We continuously invest in the most advanced instrumentation and bioinformatic platforms to stay at the forefront of the field.
Absolute Confidentiality: We operate under strict confidentiality agreements to protect your valuable intellectual property.
Comprehensive Support: From initial consultation to post-delivery support, our Ph.D.-level project managers are dedicated to your success.

The precise sequence of your human or humanized antibody is within reach. Secure the foundation of your research and development programs with the industry's most trusted De Novo Antibody Sequencing service.

Explore Our Comprehensive Antibody Services

Leverage our integrated service portfolio to accelerate your antibody projects. Once your sequence is determined, explore our related offerings:

Contact us today to discuss your project and discover how our expertise can accelerate your path to therapeutic success.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q. What is de novo antibody sequencing, and why is it important?

A: De novo antibody sequencing is the process of determining the complete amino acid sequence of an antibody directly from the purified protein itself, without any prior knowledge of the DNA, RNA, or the hybridoma cell line that produced it. This technology is critical for several reasons:

Rescuing Valuable Antibodies: When a hybridoma cell line is lost, becomes unstable, or undergoes genetic drift, de novo sequencing is the only way to perfectly preserve the antibody's sequence for future recombinant production.
Securing Intellectual Property: A precise and verified amino acid sequence is an indispensable component of a strong patent application for a novel antibody therapeutic.
Accelerating Biosimilar Development: The foundational first step in creating a biosimilar drug is to obtain the exact sequence of the originator molecule.
Ensuring Reproducibility: Inconsistent results between different antibody batches can derail research. Sequencing confirms the identity of the antibody, eliminating sequence variation as a source of discrepancy.

Q: How does Creative Biolabs' de novo sequencing differ from other providers?

A: Our primary advantages lie in our unparalleled accuracy and technological depth.

Definitive Isoleucine/Leucine (I/L) Determination: Differentiating between the isobaric amino acids Isoleucine (I) and Leucine (L) is one of the greatest challenges in mass spectrometry. Creative Biolabs has proprietary fragmentation methods and algorithms that provide 100% accurate determination of I/L, which is crucial for the biological function of the resulting recombinant antibody.
100% Coverage Guaranteed by Multi-Enzyme Strategy: We use a panel of up to 5-8 different enzymes to digest the antibody, generating a vast collection of overlapping peptide fragments. This comprehensive approach ensures that every single amino acid from the N- to C-terminus of both heavy and light chains is covered.
Cutting-Edge MS Platforms and Bioinformatics: We utilize industry-leading high-resolution mass spectrometers, like the Orbitrap Fusion Lumos, combined with our proprietary Database Assisted Shotgun Sequencing (DASS) platform to resolve even the most complex antibody sequences and post-translational modifications.

Q: What are the sample requirements for de novo human/humanized antibody sequencing?

A: All we require is 50-100 µg of purified antibody at >95% purity. Our low sample requirement means even your most precious antibodies can be successfully sequenced. We can sequence all isotypes (IgG, IgM, IgA, etc.) as well as antibody fragments such as Fab and scFv.

Q: Can you detect post-translational modifications (PTMs) on my antibody?

A: Yes. Our high-resolution mass spectrometry platform and advanced data analysis software are adept at identifying and localizing a wide range of common PTMs, such as glycosylation, oxidation, and deamidation. The final report will include a detailed summary of all identified modifications and their precise locations on the sequence.

Q: Is your service applicable to antibodies from non-human species?

A: Absolutely. Our de novo sequencing platform is species-agnostic and has been successfully used to sequence antibodies from a wide variety of species, including mouse, rat, rabbit, camelid, chicken, and more. While this page focuses on human/humanized antibodies, our technology and expertise are fully capable of sequencing an antibody from any species. Please visit our related service pages or contact us directly.

Q: How does Creative Biolabs ensure the confidentiality of my project?

A: We treat our clients' intellectual property with the utmost importance. We execute strict Confidentiality and Non-Disclosure Agreements (CDA/NDA) before any project begins. All project data is stored on secure, access-controlled servers. We guarantee that your sequence and project-related information will never be shared with any third party without your explicit consent.

Reference

Schulte, Douwe, Weiwei Peng, and Joost Snijder. "Template-based assembly of proteomic short reads for de novo antibody sequencing and repertoire profiling." Analytical chemistry 94.29 (2022): 10391-10399. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1021/acs.analchem.2c01300

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.